Anteris Technologies Global Corp 2025年季度报告

Item 3.Quantitative and Qualitative Disclosures About Market Risk Item 4.Controls and Procedures PART IIOTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk Factors. Item 3. Defaults Upon Senior Securities Item 5.Other InformationItem 6.Exhibits2 “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,”“should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward- to, statements about:our current and future research and development (“R&D”) activities, including clinical testing and manufacturing and related costs and timing;sufficiency of our capital resources;our product development and business strategy, including the potential size of the markets for our products andfuture development and/or expansion of our products in our markets;our ability to commercialize products and generate product revenues; risks facing our operations and intellectual property.We have based the forward-looking statements contained in this Form 10-Q largely on our current expectations, estimates, should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basisfor each forward-looking statement contained in this Form 10-Q, we cannot guarantee that the future results, levels of activity,performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. The forward-looking statements made in this Form 10-Q relate only to events as of the date on which the statements aremade. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result ofnew information, future events or otherwise. The Private Securities Litigation Reform Act of 1995 and Section 27A of the SecuritiesAct do not protect any forward-looking statements that we make within this Form 10-Q. understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-lookingstatements in this Form 10-Q by these cautionary statements. 1,864 Other comprehensive loss---174-1Common stock issued122,271-485--4 Balance at March 31, 202536,062,084352,224(10,717)(2 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Loss after income tax Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization expenseEquity-settled stock-based compensation Net foreign exchange losses/(gains) Other items Accounts receivable, prepayments and other assets(324)Inventories150 NET CASH USED IN OPERATING ACTIVITIES(21,489)CASH FLOWS FROM INVESTING ACTIVITIESAcquisition of plant and equipment(248) NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES1,110CASH FLOWS FROM FINANCING ACTIVITIES Repayment of debt(547)Principal payments under finance lease obligations(1) Effect of exchange rate movements on cash, cash equivalents and restricted cash(33) Balance at end of period48,955 SUPPLEMENTAL CASH FLOW INFORMATIONOperating cash flows relating to operating leases The accompanying notes are an integral part of these consolidated financial statements. DESCRIPTION OF BUSINESS Anteris Technologies Global Corp. (“ATGC,” “Anteris,” “Company,” “we,” “us,” or “our”) was incorporated in Delaware on January On December 16, 2024, the Company received all the issued and outstanding shares of ATL pursuant to a scheme of arrangement under Australian law between ATL and its shareholders (the “Scheme”) under Part 5.1 of the Australian Corporations Act 2001 (Cth)(the “Corporations Act”). Contemporaneously with implementation of the Scheme, ATL cancelled all existing options it had outstanding in exchange for the ATGC issuing replacement options to acquire shares of ATGC’s common stock, par value $0.0001pershare (“Common Stock”) pursuant to a scheme of arrangement between ATL and its option holders (the “Option Scheme”) under Part 5.1 of the Corporations Act. Prior to completion of the reverse recapitalization, ATGC had no business or operations and following completion of the reverserecapitalization, the business and operations of ATGC consist solely of the business and operations of ATL and its subsidiaries. As a financial statements of ATL became the historical financial statements of ATGC as a continuation of the predecessor. On December 16, 2024, the Company completed the reverse recapitalization and an initial public offering (“IPO”) of14,800,000shares of Common Stock.ATGC’s principal activities consist of: shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar blood flow.This new class of technology can be used to treat